Arbutus Biopharma Corporation
US ˙ NasdaqGS ˙ CA03879J1003

SecurityABUS / Arbutus Biopharma Corporation
InstitutionMorgan Stanley
Latest Disclosed Ownership25,910,337 shares
Ownership 13.50%
Morgan Stanley ownership in ABUS / Arbutus Biopharma Corporation

2026-02-11 - Morgan Stanley has filed an SCHEDULE 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 25,910,337 shares of Arbutus Biopharma Corporation (US:ABUS). This represents 13.5 percent ownership of the company. In their previous filing dated 2025-02-03 , Morgan Stanley had reported owning 21,524,661 shares, indicating an increase of 20.38 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File
Date		Effective
Date		Form Prev
Shares		 Latest
Shares		 ΔShares
(Percent)		 Ownership
(Percent)		 ΔOwnership
(Percent)
2026-02-11 2026-02-11 13G/A 21,524,661 25,910,337 20.38 13.50 18.42
2025-02-03 2025-02-03 13G/A 19,392,488 21,524,661 10.99 11.40 10.68
2024-06-10 2024-06-10 13G 1,438,264 19,392,488 1,248.33 10.30 505.88
2021-02-10 2021-02-10 13G/A 3,497,578 1,438,264 -58.88 1.70 -66.67
2020-07-16 2020-07-16 13G 3,497,578 5.10

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 25,891,480 -811,296 -3.04 116,512 -9.29 0.0070
2026-05-27 2025-12-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 26,702,776 2,252,164 9.21 128,440 15.71 0.0077
2026-02-13 2025-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 26,702,776 2,252,164 128,440 0.0077
2026-05-27 2025-09-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 24,450,612 288,229 1.19 111,006 48.68 0.0067
2025-11-14 2025-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 24,450,612 288,229 111,006 0.0067
2025-08-15 2025-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 24,162,383 369,994 1.56 74,662 -10.08 0.0049
2025-05-15 2025-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 23,792,389 1,205,471 5.34 83,035 12.42 0.0059
2025-05-15 2024-12-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 22,586,918 878,467 4.05 73,859 -11.63 0.0052
2025-02-14 2024-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 22,586,918 878,467 73,859 0.0052
2025-05-14 2024-09-30 13F/A-2 ARBUTUS BIOPHARMA COM 03879J100 21,708,451 748,183 3.57 83,578 29.04 0.0061
2025-02-14 2024-09-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 21,708,451 748,183 83,578 0.0061
2024-11-14 2024-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 21,708,451 748,183 83,578 0.0061
2025-05-14 2024-06-30 13F/A-2 ARBUTUS BIOPHARMA COM 03879J100 20,960,268 12,129,971 137.37 64,767 184.29 0.0050
2024-10-17 2024-06-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 20,960,268 12,129,971 64,767 0.0050
2024-08-14 2024-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 20,960,268 12,129,971 64,767 0.0050
2024-10-17 2024-03-31 13F/A-2 ARBUTUS BIOPHARMA COM 03879J100 8,830,297 1,846,185 26.43 22,782 30.48 0.0018
2024-08-16 2024-03-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 8,830,297 1,846,185 22,782 0.0018
2024-05-15 2024-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 8,830,297 1,846,185 22,782 0.0018
2024-08-16 2023-12-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 6,984,112 1,722,982 32.75 17,460 63.48 0.0015
2024-02-13 2023-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 6,984,112 1,722,982 17,460 0.0015
2023-11-15 2023-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 5,261,130 180,834 3.56 10,680 -8.59 0.0011
2023-08-14 2023-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 5,080,296 197,689 4.05 11,685 -21.02 0.0012
2023-05-15 2023-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 4,882,607 4,640,713 1,918.49 14,794 2,527.71 0.0016
2023-02-14 2022-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 241,894 29,888 14.10 564 39.01 0.0001
2022-11-14 2022-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 212,006 -6,948 -3.17 405 -31.93 0.0001
2022-10-27 2022-06-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 218,954 21,773 11.04 595 1.36 0.0001
2022-08-15 2022-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 218,954 21,773 595 0.0000
2022-10-27 2022-03-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 197,181 -41,826 -17.50 587 -36.88 0.0001
2022-05-13 2022-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 197,181 -41,826 587 0.0001
2022-02-14 2021-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 239,007 17,823 8.06 930 -2.11 0.0001
2021-11-15 2021-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 221,184 -70,597 -24.20 950 7.47 0.0001
2021-08-23 2021-06-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 291,781 -838,590 -74.19 884 -76.51 0.0001
2021-08-16 2021-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 291,781 -838,590 884 0.0000
2021-05-17 2021-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 1,130,371 -291,893 -20.52 3,764 -25.45 0.0006
2021-02-16 2020-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 1,422,264 -1,487,452 -51.12 5,049 -44.56 0.0008
2020-11-13 2020-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 2,909,716 -443,821 -13.23 9,107 49.20 0.0018
2020-08-14 2020-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 3,353,537 1,306,529 63.83 6,104 195.31 0.0014
2020-05-26 2020-03-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 2,047,008 175,920 9.40 2,067 -60.27 0.0006
2020-05-15 2020-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 2,047,008 175,920 2,067 158.7887
2020-02-14 2019-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 1,871,088 229,442 13.98 5,202 107.75 0.0012
2019-11-14 2019-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 1,641,646 31,760 1.97 2,504 -25.23 0.0007
2019-08-14 2019-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 1,609,886 643,955 66.67 3,349 -3.15 0.0009
2019-05-15 2019-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 965,931 -119,644 -11.02 3,458 -16.82 0.0010
2019-02-14 2018-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 1,085,575 60,222 5.87 4,157 -57.10 0.0012
2019-04-23 2018-09-30 13F/A-2 ARBUTUS BIOPHARMA COM 03879J100 1,025,353 289,556 39.35 9,690 80.38 0.0024
2018-11-20 2018-09-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 1,025,353 0 9,690 0.0024
2018-11-14 2018-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 1,025,353 289,556 9,690
2019-04-23 2018-06-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 735,797 221,801 43.15 5,372 109.03 0.0015
2018-08-14 2018-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 735,797 221,801 5,372
2019-04-23 2018-03-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 513,996 -114,681 -18.24 2,570 -19.03 0.0007
2018-05-14 2018-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 513,996 -114,681 2,570
2019-04-23 2017-12-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 628,677 207,076 49.12 3,174 21.42 0.0009
2018-02-14 2017-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 628,677 207,076 3,174
2017-11-14 2017-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 421,601 94,353 28.83 2,614 121.90 0.0008
2017-08-11 2017-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 327,248 34,553 11.81 1,178 23.87 0.0004
2017-05-22 2017-03-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 292,695 14,695 5.29 951 39.65 0.0003
2017-05-12 2017-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 292,695 951
2017-02-22 2016-12-31 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 278,000 143,285 106.36 681 46.77 0.0002
2017-02-13 2016-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 278,000 681
2016-11-10 2016-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 134,715 34,862 34.91 464 33.72 0.0002
2016-08-12 2016-06-30 13F ARBUTUS BIOPHARMA COM 03879J100 99,853 59,244 145.89 347 107.78 0.0001
2016-05-12 2016-03-31 13F ARBUTUS BIOPHARMA COM 03879J100 40,609 18,591 84.44 167 70.41 0.0001
2016-02-09 2015-12-31 13F ARBUTUS BIOPHARMA COM 03879J100 22,018 -105,020 -82.67 98 -87.34 0.0000
2016-02-08 2015-09-30 13F/A-1 ARBUTUS BIOPHARMA COM 03879J100 127,038 127,038 774 0.0003
2015-11-09 2015-09-30 13F ARBUTUS BIOPHARMA COM 03879J100 127,038 774
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.